MARCY EPSTEIN: Open Payments
NPI 1326371105 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,125 in 68 payments from 7 companies in 2025. Trend: 2023 $715 · 2024 $323 · 2025 $2,125
Food & beverage: $2,038Education: $87
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $633 |
| Teva Pharmaceuticals USA, Inc. | 26 | $575 |
| E.R. Squibb & Sons, L.L.C. | 10 | $404 |
| Otsuka America Pharmaceutical, Inc. | 11 | $341 |
| Janssen Pharmaceuticals, Inc | 2 | $136 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Lundbeck LLC | 1 | $16 |
Products named: UZEDY, COBENFY, ARISTADA, LYBALVI, ABILIFY MAINTENA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE.
Industry payments across CA — which companies pay providers there.
